🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 15117B202 (prev. 15117B103 )
- Market Cap
- Small Cap · $200 Million
- Previous Symbol
- AVAN (changed 10/1/2008)
- Previous Name
- AVANT Immunotherapeutics, Inc.
Business: Celldex Therapeutics, Inc is engaged in developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Notes: Feb. 08, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. <p> Mar 7, 2008 - AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the completed merger of Callisto Corporation, its wholly-owned subsidiary, with and into Celldex Therapeutics, Inc., Oct, 1, 2008; AVANT Immunotherapeutics announces Name Change to Celldex Therapeutics inc. and shares of the Company's common stock will be listed on NASDAQ under the ticker symbol "CLDX".
Company Contact
- CEO
- Anthony S. Marucci
- CFO
- Sam Martin
- Headquarters
- Perryville III Building, 53 Frontage Road, Suite 220, Hampton, NJ 08827
- Phone
- 908-200-7500
- Investor Relations
- Sarah Cavanaugh · 781-433-3161 · scavanaugh@celldex.com